On the same day Roivant Sciences announced the formation of autoimmune-focused Priovant Therapeutics in collaboration with Pfizer, the company also revealed that it has discontinued development of several assets following a pipeline reprioritization.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,